101 related articles for article (PubMed ID: 9230206)
41. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.
Bontkes HJ; de Gruijl TD; Walboomers JM; van den Muysenberg AJ; Gunther AW; Scheper RJ; Meijer CJ; Kummer JA
Br J Cancer; 1997; 76(10):1353-60. PubMed ID: 9374383
[TBL] [Abstract][Full Text] [Related]
42. Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers.
Honda T; Ando M; Ando J; Ishii M; Sakiyama Y; Ohara K; Toyota T; Ohtaka M; Masuda A; Terao Y; Nakanishi M; Nakauchi H; Komatsu N
Mol Ther; 2020 Nov; 28(11):2394-2405. PubMed ID: 32710827
[TBL] [Abstract][Full Text] [Related]
43. Immunobiology of HPV Infection.
Garcia-Chacon R; Velasco-Ramirez SF; Flores-Romo L; Daneri-Navarro A
Arch Med Res; 2009 Aug; 40(6):443-8. PubMed ID: 19853184
[No Abstract] [Full Text] [Related]
44. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.
Furukawa Y; Ishii M; Ando J; Ikeda K; Igarashi KJ; Kinoshita S; Azusawa Y; Toyota T; Honda T; Nakanishi M; Ohshima K; Masuda A; Yoshida E; Kitade M; Porteus M; Terao Y; Nakauchi H; Ando M
Cell Rep Med; 2023 Dec; 4(12):101327. PubMed ID: 38091985
[TBL] [Abstract][Full Text] [Related]
45. Prospects for immunotherapy in cervical cancer.
Immunol Today; 1996 Jul; 17(7):299. PubMed ID: 8763810
[No Abstract] [Full Text] [Related]
46. The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.
Santegoets SJ; Welters MJP; Schrikkema DS; Freriks MR; Kok H; Weissbrich B; van den Branden A; Linnemann C; Schumacher TN; Adhikary S; Bendle G; van der Burg SH
Cancer Immunol Immunother; 2023 Jun; 72(6):1553-1565. PubMed ID: 36526910
[TBL] [Abstract][Full Text] [Related]
47. Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.
Norouzian M; Mehdipour F; Ashraf MJ; Khademi B; Ghaderi A
BMC Immunol; 2022 Nov; 23(1):56. PubMed ID: 36376825
[TBL] [Abstract][Full Text] [Related]
48. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy.
Muntinga CLP; de Vos van Steenwijk PJ; Bekkers RLM; van Esch EMG
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268523
[TBL] [Abstract][Full Text] [Related]
49. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
Mbuya W; Held K; Mcharo RD; Haule A; Mhizde J; Mnkai J; Mahenge A; Mwakatima M; Sembo M; Mwalongo W; Agrea P; Hoelscher M; Maboko L; Saathoff E; Geisenberger O; Rwegoshora F; Torres L; Koup RA; Kroidl A; Chachage M; Geldmacher C
Front Immunol; 2021; 12():742861. PubMed ID: 34759925
[TBL] [Abstract][Full Text] [Related]
50. Potential role of micro ribonucleic acids in screening for anal cancer in human papilloma virus and human immunodeficiency virus related malignancies.
Al Bitar S; Ballouz T; Doughan S; Gali-Muhtasib H; Rizk N
World J Gastrointest Pathophysiol; 2021 Jul; 12(4):59-83. PubMed ID: 34354849
[TBL] [Abstract][Full Text] [Related]
51. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
Zhang Y; Yu M; Jing Y; Cheng J; Zhang C; Cheng L; Lu H; Cai MC; Wu J; Wang W; Lou W; Qiu L; Tan L; Lu H; Yin X; Zhuang G; Di W
Br J Cancer; 2021 Jan; 124(2):414-424. PubMed ID: 33087896
[TBL] [Abstract][Full Text] [Related]
52. Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression.
Grochot RM; Brollo J; Neto FR; Tregnago AC; Scholze C; Norris R; Silva S; Weschenfelder DC; Reiriz AB; Michelin L; Pasqualotto FF
Cancer Manag Res; 2019; 11():4597-4605. PubMed ID: 31191020
[No Abstract] [Full Text] [Related]
53. Risk factors for cytological progression in HPV 16 infected women with ASC-US or LSIL: The Korean HPV cohort.
So KA; Kim SA; Lee YK; Lee IH; Lee KH; Rhee JE; Kee MK; Cho CH; Hong SR; Hwang CS; Jeong MS; Kim KT; Ki M; Hur SY; Park JS; Kim TJ
Obstet Gynecol Sci; 2018 Nov; 61(6):662-668. PubMed ID: 30474012
[TBL] [Abstract][Full Text] [Related]
54. Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.
Berry J; Glasgow SC
Clin Colon Rectal Surg; 2018 Nov; 31(6):321-327. PubMed ID: 30397391
[TBL] [Abstract][Full Text] [Related]
55. The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.
Woodby B; Scott M; Bodily J
Prog Mol Biol Transl Sci; 2016; 144():169-238. PubMed ID: 27865458
[TBL] [Abstract][Full Text] [Related]
56. CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study.
Santos EU; Lima GD; Oliveira Mde L; Heráclio Sde A; Silva HD; Crovella S; Maia Mde M; Souza PR
Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):174-80. PubMed ID: 26982176
[TBL] [Abstract][Full Text] [Related]
57. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection.
Senba M; Mori N
Oncol Rev; 2012 Oct; 6(2):e17. PubMed ID: 25992215
[TBL] [Abstract][Full Text] [Related]
58. Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model.
Fazeli M; Soleimanjahi H; Dadashzadeh S
Iran J Cancer Prev; 2015; 8(1):18-23. PubMed ID: 25821567
[TBL] [Abstract][Full Text] [Related]
59. Warts and all: human papillomavirus in primary immunodeficiencies.
Leiding JW; Holland SM
J Allergy Clin Immunol; 2012 Nov; 130(5):1030-48. PubMed ID: 23036745
[TBL] [Abstract][Full Text] [Related]
60. Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.
Scholl SM; Kenter G; Kurzeder C; Beuzeboc P
ISRN Oncol; 2011; 2011():403098. PubMed ID: 22091418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
